PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-29.38%
Both companies show declining cash positions (-29.38% vs GNPX's -61.17%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Below half of GNPX's -61.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of GNPX's 2.00%. David Dodd sees a leaner approach to short-term items.
-29.50%
0.5-0.75x GNPX's -50.62%. Martin Whitman might see risk if this hampers near-term financial flexibility.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
0.75-0.9x GNPX's -36.31%. Bill Ackman questions if competitor invests more aggressively for growth.
-13.35%
Less than half of GNPX's -38.99%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
-6.76%
Less than half of GNPX's 144.34%. David Dodd sees fewer expansions in other current obligations.
-9.79%
Less than half of GNPX's 13.75%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Less than half of GNPX's 13.75%. David Dodd sees far fewer liability expansions relative to competitor.
0.31%
Less than half of GNPX's 37.22%. David Dodd sees fewer share issuances vs. competitor.
-2.40%
0.75-0.9x GNPX's -2.94%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-68.44%
Similar yoy to GNPX's -64.03%. Walter Schloss sees parallel net worth trends.
-29.38%
0.75-0.9x GNPX's -36.31%. Bill Ackman wonders if competitor invests or leverages more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
28.92%
Less than half of GNPX's 61.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.